
        <html>
        <head>
            <style>
                body { font-family: Arial, sans-serif; line-height: 1.6; margin: 20px; }
                h3 { color: #333; }
                .question { margin-bottom: 15px; }
                .options { margin-left: 20px; margin-bottom: 10px; }
                .solution { background: #f8f9fa; padding: 10px; border-left: 4px solid #007bff; }
                .credits { text-align: center; margin-top: 20px; font-size: 18px; }
                .rainbow-text { 
                    background: linear-gradient(90deg, red, orange, yellow, green, blue, indigo, violet); 
                    -webkit-background-clip: text; 
                    color: transparent; 
                    font-weight: bold; 
                }
            </style>
        </head>
        <body>
        
            <div class="question">
                <h3>Question No: 1</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is a WHO-approved dengue vaccine for individuals seropositive for dengue virus? (Vector borne diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dengvaxia</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>DENVax</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Tetravax &ndash;DV</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>TDENV PIV</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Dengvaxia</strong> is a WHO-approved vaccine for individuals <strong>seropositive</strong> for <strong>dengue virus</strong>. It is currently licensed in 20 countries.</li>
<li>A pre-vaccination screening strategy must be adopted so that only dengue-seropositive individuals are vaccinated. It is indicated for individuals between <strong>9 to 16 years</strong>. It is given in 3 doses, 6 months apart. Booster doses are not required.</li>
<li>However, it carries an increased <strong>risk of severe</strong> dengue in those who experience their <strong>first</strong> natural dengue infection <strong>after vaccination</strong> (seronegative individuals).</li>
</ul>
<p><strong>Note: TV003,</strong> a live, attenuated, <strong>tetravalent dengue vaccine is</strong> currently in Phase-3 trials. It has shown <strong>efficacy</strong> in promoting immunity in both <strong>seropositive and seronegative</strong> individuals between <strong>2-59 years</strong> of age.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 2</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Monkey pox was declared as a Public Health Emergency of International Concern (PHEIC) by World Health Organization (WHO) in: (Zoonotic diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Aug 2024</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>July 2023</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Dec 1970</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>March 2020</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Public Health Emergency: Mpox </strong></p>
<ul>
<li>Mpox, earlier referred to as <strong>Monkey pox,</strong> is a viral disease of zoonotic origin. Recognizing the global threat posed by Mpox, WHO had declared it as a <strong>Public Health Emergency of International Concern</strong> (PHEIC) in <strong>August 2024.</strong></li>
<li>The first case of monkey pox in humans was reported in 1970 in the Democratic Republic of Congo.</li>
</ul>
<p><img title="image002.png" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/b51228a7-1aa9-4275-9a48-78449b79f43a.png" alt="" width="558" height="256" /></p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 3</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>An 18-year-old went on an exchange program to Singapore. As an adventurous eater, she tried clams and oysters on a cruise ship. 2 days later, she developed fever, nausea, vomiting, and diarrhea. What is the causative agent? (Food borne diseases, Nutrition assessment and education, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Adenovirus</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rotavirus</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Norwalk virus</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Enterovirus</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The clinical scenario describes a case of <strong>Norwalk</strong> It is the most common cause of diarrhea in <strong>older children</strong> and <strong>adults.</strong></li>
<li>They occur in group settings such as <strong>banquet halls, cruise ships, dormitories</strong>, and <strong>campgrounds,</strong> where outbreak sources are usually contaminated food and/or water. Potential sources of contaminated food include <strong>shellfish</strong> such as <strong>clams</strong> and <strong>oysters,</strong> which are contaminated by water.</li>
<li>Clinical features are nausea, vomiting, watery diarrhea, abdominal pain. Symptoms of gastroenteritis develop <strong>12 to 48 hours</strong> after being exposed to norovirus.</li>
</ul>
<p><img title="image004.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/c8e13e97-6235-45c9-a550-c85833a003d8.jpg" alt="" width="266" height="294" /></p>
<p><strong>Figure</strong>: Electron Micrograph of Norovirus (Norwalk virus)</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 4</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following symptoms is&nbsp;NOT&nbsp;associated with monkey pox virus? ((Vector borne diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bloody diarrhea</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Muscle aches</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Swollen glands</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rash lasting 2 to 4 weeks</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Clinical Features of Monkey Pox</strong></p>
<ul>
<li><strong>Prodromal symptoms</strong> (0-5 days) include:
<ul>
<li>Fever, myalgia and headache</li>
<li>Sore throat and cough</li>
<li>Swollen lymph nodes</li>
</ul>
</li>
<li><strong>Rash</strong> (within 1-3 days of fever onset) lasting for around 2-4 weeks and progresses through 4 stages- macular, papular, vesicular, to pustular before scabbing and desquamation. <strong>A person is contagious until all scabs on the skin have fallen off</strong> and a fresh layer of intact skin has formed underneath.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 5</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is true about the Revised National Tuberculosis Control Programme? (Infectious diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Follow-up sputum smear examination at the end of intensive phase only</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Directly Observed Treatment Short course strategy is applied</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Treatment is only given to smear positive cases</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>MDR TB is resistance to either rifampicin or isoniazid</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>DOTS stands for <strong>Directly Observed Treatment Short-course</strong> and is given by peripheral and voluntary health workers.</p>
<p><strong>Recent updates in RNTCP: </strong></p>
<ul>
<li>Active case finding for TB has been started.</li>
<li>Follow up:</li>
<li>On treatment: Monthly follow up.</li>
<li>After treatment: Follow up at 6, 12, 18 and 24 months.</li>
<li>A sputum smear examination must be done at the <strong>end of</strong> <strong>intensive phase</strong> (IP) and at the <strong>end of treatment.</strong></li>
</ul>
<p><strong>Anti-Tubercular Treatment (ATT) Regimen for TB Patients </strong></p>
<ul>
<li>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP),</strong> treatment of TB is now primarily based on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases.</li>
<li>All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>).</li>
</ul>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 32.7338%;" width="232">
<p><strong>Type of TB Case</strong></p>
</td>
<td style="width: 32.554%;" width="232">
<p><strong>Intensive Phase</strong></p>
</td>
<td style="width: 34.7122%;" width="232">
<p><strong>Continuation Phase</strong></p>
</td>
</tr>
<tr>
<td style="width: 32.7338%;" width="232">
<p>New and previously treated cases (H and R sensitive)</p>
</td>
<td style="width: 32.554%;" width="232">
<p>2 months H R Z E</p>
</td>
<td style="width: 34.7122%;" width="232">
<p>4 months H R E</p>
</td>
</tr>
</tbody>
</table>
<p><strong>Classification based on drug resistance</strong></p>
<p>The cases are classified as:</p>
<ul>
<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1<sup>st</sup> line anti-TB drug only.</li>
<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1<sup>st</sup> line anti-TB drug, other than Rifampicin and Isoniazid.</li>
<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to rifampicin with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>
<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to both Isoniazid and Rifampicin.</li>
<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a fluoroquinolone (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are Bedaquiline and Linezolid)</li>
</ul>
<p><strong>Table: Standard DR TB regimen</strong></p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 30.7554%;" width="217">
<p><strong>Regimen class</strong></p>
</td>
<td style="width: 34.5324%;" width="248">
<p><strong>Drugs</strong></p>
</td>
<td style="width: 34.5324%;" width="263">
<p><strong>Comments</strong></p>
</td>
</tr>
<tr>
<td style="width: 30.7554%;" width="217">
<p><strong>H mono-resistant / poly-drug resistant TB regimen</strong></p>
</td>
<td style="width: 34.5324%;" width="248">
<p>Lfx R E Z for 6 months</p>
</td>
<td style="width: 34.5324%;" width="263">
<p>6 Months&rsquo; long</p>
<p>Oral drugs only</p>
</td>
</tr>
<tr>
<td style="width: 30.7554%;" width="217">
<p><strong>BPaLM regime (New MDR regime by WHO)</strong></p>
</td>
<td style="width: 34.5324%;" width="248">
<p>Bdq Pa Lzd Mfx for 6 months</p>
</td>
<td style="width: 34.5324%;" width="263">
<p>6 Months long</p>
</td>
</tr>
<tr>
<td style="width: 30.7554%;" width="217">
<p><strong>9- 11 months shorter oral Bedaquiline regime (Shorter MDR)</strong></p>
</td>
<td style="width: 34.5324%;" width="248">
<p><strong>Intensive Phase: </strong></p>
<p>Lfx Bdq (6 months) Cfz Z Hh E Eto for 4- 6 months</p>
<p>&nbsp;</p>
<p><strong>Continuation phase: </strong></p>
<p>Lfx Cfz Z E for 5 months</p>
</td>
<td style="width: 34.5324%;" width="263">
<p>9-11 Months long totally</p>
<p>&nbsp;</p>
<p>Injectable used in intensive phase.</p>
</td>
</tr>
<tr>
<td style="width: 30.7554%;" width="217">
<p><strong>Longer MDR TB regimen</strong></p>
</td>
<td style="width: 34.5324%;" width="248">
<p>Bdq (6 months or longer) Lfx Lzd Cfz Cs</p>
</td>
<td style="width: 34.5324%;" width="263">
<p>18-20 months&rsquo; long</p>
<p>&nbsp;</p>
<p>Oral drugs only</p>
<p>&nbsp;</p>
<p>This regimen is used for DR TB patients for 20 months.</p>
</td>
</tr>
</tbody>
</table>
<p><strong>Table: Criteria for patients to receive standard Drug Resistant TB regimen:</strong></p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 31.8345%;" width="255">
<p><strong>Standard Drug Resistant TB Regimen</strong></p>
</td>
<td style="width: 36.3309%;" width="246">
<p><strong>Inclusion Criteria</strong></p>
</td>
<td style="width: 31.6547%;" width="227">
<p><strong>Exclusion Criteria</strong></p>
</td>
</tr>
<tr>
<td style="width: 31.8345%;" width="255">
<p>H mono-resistant / poly-drug resistant TB regimen.</p>
</td>
<td style="width: 36.3309%;" width="246">
<p><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></p>
</td>
<td style="width: 31.6547%;" width="227">
<p>No specific criteria</p>
</td>
</tr>
<tr>
<td style="width: 31.8345%;" width="255">
<p><strong>BPaLM regimen (new MDR TB regimen by WHO)</strong></p>
</td>
<td style="width: 36.3309%;" width="246">
<p><strong>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB </strong>(MDR/RR-TB and resistance to fluoroquinolones).</p>
<p><strong>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Those with <strong>confirmed</strong> pulmonary TB and all forms of extra pulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</p>
<p><strong>3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Patients <strong>&gt;14 years of age</strong>.</p>
</td>
<td style="width: 31.6547%;" width="227">
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>Pregnant and lactating women</p>
</td>
</tr>
<tr>
<td style="width: 31.8345%;" width="255">
<p><strong>9- 11 months shorter MDR TB regimen</strong></p>
</td>
<td style="width: 36.3309%;" width="246">
<p>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</p>
</td>
<td style="width: 31.6547%;" width="227">
<p><strong>Non drug sensitivity test based criteria: </strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any extra pulmonary disease in PLHIV</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disseminated meningeal or central nervous system TB</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intolerance to any drug in the shorter MDR TB regimen</p>
<p><strong>Drug sensitivity test based criteria: </strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If DST/DRT result for FQ or SLI is resistant (DR TB)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Presence of InhA mutation</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resistant to Z</p>
</td>
</tr>
<tr>
<td style="width: 31.8345%;" width="255">
<p>Longer MDR TB regimen</p>
</td>
<td style="width: 36.3309%;" width="246">
<p>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</p>
</td>
<td style="width: 31.6547%;" width="227">
<p>None</p>
</td>
</tr>
</tbody>
</table>
<p>FQ: Fluoroquinolone, SLI: Second Line Injectable, PLHIV: People Living with HIV, Lfx: Levofloxacin, Pa: Pretomanid, H: Isoniazid, Hh: High Dose Isoniazid, R: Rifampicin, E: Ethambutol, Z: Pyrazinamide Mfx: Moxitioxacin, Km: Kanamycin, Am: Amikacin, Eto: Ethionamide, Cfz: Clofazimine, Bdq: Bedaquiline, Lzd: Linezolid, CS: Cycloserine.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 6</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following statements is true about monkey pox virus transmission? (Zoonotic diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Transmission can occur from symptom onset until the rash forms scabs.</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Respiratory secretions are not a source of transmission.</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Monkey pox can be transmitted by touching items worn by someone with the virus.</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Monkey pox cannot be transmitted to the fetus through the placenta.</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>According to the CDC, monkey pox spreads in several ways.&nbsp;The virus can spread from person to person through:
<ul>
<li>Direct contact with the infectious rash, scabs, or body fluids.</li>
<li>Respiratory secretions during prolonged face-to-face contact, or during intimate physical contact, such as kissing, cuddling, or sex.</li>
<li>Touching items (such as clothing or linens) that were in contact with an infectious rash or body fluids.</li>
<li>During pregnancy, the virus may be passed to the fetus, or to the newborn during or after birth.</li>
</ul>
</li>
<li>It&rsquo;s also possible for people to get monkey pox from infected animals, either by being scratched or bitten by the animal or by preparing or eating meat or using products from an infected animal.</li>
<li>Monkey pox can spread from the time symptoms start until the rash has fully healed and a fresh layer of skin has formed.<sup> </sup>The illness typically lasts 2 to 4 weeks.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 7</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following drugs is not used in the management of a patient with MDR-TB under latest WHO regimen adopted by MOHFW? (Infectious diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pretomanid</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Levofloxacin</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bedaquiline</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Moxifloxacin</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>New regimen for the treatment of MDR TB adopted by MOHFW </strong></p>
<p>WHO recommended a new <strong>6-month BPaLM</strong> regimen for treating MDR TB in 2022. The regimen consisting of <strong>Bedaquiline, Pretomanid, Linezolid</strong> and <strong>Moxifloxacin</strong> has been now adopted by the MOHFW as a more effective option than the previous BpaL regimen.</p>
<p><strong>Indications: </strong></p>
<ul>
<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> (MDR/RR-TB and resistance to fluoroquinolones).</li>
<li>Those with <strong>confirmed</strong> pulmonary TB and extra pulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>
<li>Patients <strong>&gt; 14 years of age</strong>.</li>
</ul>
<p><strong>Dosage: </strong></p>
<ul>
<li><strong>Bedaquiline 100 mg</strong> tablet: 400 mg OD for 2 weeks &gt; 200 mg 3 times/week OR 200 mg daily for 8 weeks - &gt;100 mg daily</li>
<li><strong>Pretomanid 200 mg</strong> tablet OD</li>
<li><strong>Linezolid 600 mg</strong> tablet OD</li>
<li><strong>Moxifloxacin 400 mg</strong> tablet OD</li>
</ul>
<p><strong>Precautions </strong></p>
<ul>
<li><strong>Linezolid </strong>should be continuously monitored due to risk of <strong>anemia, thrombocytopenia, optic neuritis,</strong> and <strong>peripheral neuropathy</strong>.</li>
<li>Pretomanid has limited safety and hence the regime is <strong>contraindicated </strong>in <strong>pregnan</strong>t and <strong>lactating women.</strong></li>
<li>Individuals with CVS disease, elevated liver enzymes, or very low BMI.</li>
</ul>
<p><strong>Abbreviations: </strong></p>
<ul>
<li>MDR/RR-TB: Multidrug-resistant TB (MDR-TB) or rifampicin-resistant TB (RR-TB)</li>
<li>Multidrug-resistant TB (MDR-TB): TB resistant to rifampicin and isoniazid.</li>
<li>Extensively drug-resistant TB (XDR-TB): TB resistant to rifampicin, at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one of Bedaquiline or Linezolid.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 8</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which atypical symptom is associated with the current monkey pox outbreak as opposed to previous outbreaks? (Zoonotic diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Anogenital lesions</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Painful lesions</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>More than 20 lesions in total</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>High fever before rash appearance</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The 2022 outbreak has produced atypical symptoms when compared with previous monkey pox outbreaks. These symptoms include:
<ul>
<li>Lesions mostly confined to the genital and perianal areas, presenting with anal pain and bleeding.</li>
<li>Scant or even single lesions, or even the complete absence of skin lesions.</li>
<li>Lack of prodromal symptoms such as fever, myalgias, fatigue, and headache before the appearance of a rash.</li>
</ul>
</li>
<li>According to&nbsp;the largest international monkey pox case series to date, anogenital lesions, single genital ulcers, and mouth sores are all unique symptoms of the current monkey pox outbreak. Painful lesions, fever, swollen lymph nodes, and rash have been commonly associated with previous monkey pox outbreaks. The number of lesions continues to widely vary. Patients who are immunocompromised also widely vary in their presentations.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 9</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which family does the Nipah virus belong to? (Zoonotic diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Paramyxoviridae</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Togaviridae</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Flaviviridae</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bunyaviridae</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Nipah virus belongs to the family</li>
<li><strong>Togaviridae</strong> contains <strong>chikungunya virus</strong>.</li>
<li><strong>Flaviviridae</strong> contains yellow fever virus, <strong>dengue virus</strong>, Japanese encephalitis virus, hepatitis C virus, Zika virus</li>
<li><strong>Bunyaviridae</strong> contains sand-fly fever virus,</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 10</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>According to the US Food and Drug Administration (FDA), to avoid false results, clinicians should use which of these as samples for testing? (Laboratory methods for identifications of Microorganishms, General characteristics of Microbes, Microbiology)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Lesion swabs, taken directly from a growth or rash</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Saliva</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Serum</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rectal swabs, even in the absence of lesions</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>According to the FDA, to avoid false results, clinicians should use diagnostic specimens are taken directly from the rash &ndash; skin, fluid or crusts &ndash; collected by vigorous swabbing. Testing blood, saliva, and other samples that are not directly from a lesion can lead to false results.</li>
<li><strong>Diagnosis of Monkey pox: </strong></li>
<li>Detection of viral DNA by polymerase chain reaction (PCR).</li>
</ul>
<p><strong>Note:</strong> India has developed its own home-grown RT-PCR testing kit for Mpox. The IMDX Monkey pox Detection RT-PCR Assay, developed by healthcare services company Siemens Healthineers.</p>
<p><img title="image006.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/680c3d4f-0fb9-483b-a67d-ae8b9ffebc56.jpg" alt="" width="232" height="155" /></p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 11</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A patient is taking Linezolid 600 mg tab once a day as per the latest WHO MDR-TB regimen. The nurse should continuously monitor the patient for the risk of: (Infectious diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Optic neuritis</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Orange color urine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Watery diarrhea</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Blue-green vision</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>New regimen for the treatment of MDR TB adopted by MOHFW </strong></p>
<ul>
<li>WHO recommended a new <strong>6-month BPaLM</strong> regimen for treating MDR TB in 2022. The regimen consisting of <strong>Bedaquiline, Pretomanid, Linezolid</strong> and <strong>Moxifloxacin</strong> has been now adopted by the MOHFW as a more effective option than the previous BpaL regimen.</li>
</ul>
<p><strong>Dosage: </strong></p>
<ul>
<li><strong>Bedaquiline 100 mg</strong> tablet: 400 mg OD for 2 weeks &gt; 200 mg 3 times/week OR 200 mg daily for 8 weeks - &gt;100 mg daily</li>
<li><strong>Pretomanid 200 mg</strong> tablet OD</li>
<li><strong>Linezolid 600 mg</strong> tablet OD</li>
<li><strong>Moxifloxacin 400 mg</strong> tablet OD</li>
</ul>
<p><strong>Precautions </strong></p>
<ul>
<li><strong>Linezolid </strong>should be continuously monitored due to risk of <strong>anemia, thrombocytopenia, optic neuritis,</strong> and <strong>peripheral neuropathy</strong>.</li>
<li>Pretomanid has limited safety and hence the regime is <strong>contraindicated </strong>in <strong>pregnan</strong>t and <strong>lactating women</strong></li>
<li>Individuals with CVS disease, elevated liver enzymes, or very low BMI.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 12</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong><strong>Consider the following statements about Monkey pox:</strong></strong></p>
<p>1. Monkey pox belongs to the orthopoxvirus.</p>
<p>2. It is a RNA Virus.</p>
<p>Which of the statements given above is/are not correct? (Zoonotic diseases, Communicable diseases and National Health Programs, Community health nursing)</p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1 only</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>2 only</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Both 1 and 2</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Neither 1 nor 2</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Monkey pox belongs to the orthopoxvirus, which is a genus of viruses that also includes the variola virus which causes smallpox.</li>
<li>Mpox virus is an <strong>enveloped double-stranded DNA</strong> virus that belongs to the genus Orthopoxvirus. There is no known natural reservoir of the virus. The disease has an <strong>incubation period</strong> of 6 to 13 days (range: 5 to 21 days). The affected person is not contagious during this period.</li>
<li><strong>Period of communicability:</strong> 1-2 days before the rash to until all the scabs fall off/get subsided.</li>
<li>There are two distinct genetic clades of the monkey pox virus; the central African (Congo Basin) clade and the West African clade. The Congo Basin clade has historically caused more severe disease and was thought to be more transmissible.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 13</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following drug is contraindicated for lactating women under new WHO recommended BPaLM regimen? (Drugs used in management of high-risk pregnancies, Recognition and Management of problems during Pregnancy, Midwifery/Obstetrics and Gynecological Nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bedaquiline</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pretomanid</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Linezolid</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Moxifloxacin</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The drug used under BPaLM regimen are: -</p>
<ul>
<li><strong>Bedaquiline 100 mg</strong> tablet: 400 mg OD for 2 weeks &gt; 200 mg 3 times/week OR 200 mg daily for 8 weeks - &gt;100 mg daily</li>
<li><strong>Pretomanid 200 mg</strong> tablet OD</li>
<li><strong>Linezolid 600 mg</strong> tablet OD</li>
<li><strong>Moxifloxacin 400 mg</strong> tablet OD</li>
</ul>
<p><strong>Precautions </strong></p>
<ul>
<li><strong>Linezolid </strong>should be continuously monitored due to risk of <strong>anemia, thrombocytopenia, optic neuritis,</strong> and <strong>peripheral neuropathy</strong>.</li>
<li>Pretomanid has limited safety and hence the regime is <strong>contraindicated </strong>in <strong>pregnan</strong>t and <strong>lactating women</strong></li>
<li>Individuals with CVS disease, elevated liver enzymes, or very low BMI.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 14</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Currently, which of the following is a proven treatment for monkey pox? (Zoonotic diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antibiotics</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antiviral drugs</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Symptomatic relief</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Vaccination</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Prevention and Treatment of Monkey pox</strong></p>
<ul>
<li>Currently, there is no proven treatment of monkey pox. Treatment is aimed at relieving symptoms. <strong>Smallpox vaccinations</strong> are effective as they confer <strong>cross-protection</strong> to Mpox. Treatment of Mpox is primarily</li>
<li>Antibiotics are not used unless infection occurs as a result of worsening monkey pox.</li>
<li>Antiviral drugs may be helpful, but they have not been studied as treatment for monkey pox.</li>
<li>Vaccination is at least 85% effective in preventing monkey pox, but it will not treat monkey pox. &nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 15</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>What was the theme of World Health Day 2024? (National Health Programms, Communicable Diseases, Community Health Nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Build a fairer, healthier world</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Health for all</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>My health, my right</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Our planet, our health</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The theme of World Health Day 2024 is <strong>My health, my right.</strong></p>
<p>World Health Day is celebrated on <strong>7<sup>th</sup> April</strong> and each year a different theme is adopted such as:</p>
<ul>
<li>2024- My health, my right</li>
<li>2023- Health for all</li>
<li>2022- Our planet, our health</li>
<li>2021- Build a fairer, healthier world for everyone, everywhere</li>
<li>2020 - Support nurses and midwives</li>
<li>2018 and 2019 - Universal health coverage; everyone, everywhere</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 16</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following drugs is approved for prophylaxis against respiratory syncytial virus (RSV) infection? (Infectious disease, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ribavirin</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Omalizumab</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Nirsevimab</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Oseltamivir</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Nirsevimab</strong> is a monoclonal antibody recently approved by the FDA to be used as a <strong>prophylaxis</strong> against respiratory syncytial virus (RSV) infection.</li>
<li><strong>RSV </strong>is responsible for more than half of the cases of <strong>bronchiolitis</strong> in <strong>infants less than 1 year of age</strong>. It generally presents as a fever with cough and wheezing. It has a very high infectivity and transmission is by close contact and droplet transmission. Nasopharyngeal swabs and nasal washings are collected as samples. They are inoculated in cell culture (HeLa or Hep-2) immediately after collection. In cultured cells, RSV shows characteristic giant cells and syncytial formation.</li>
</ul>
<p><strong>Novel drug approved for prevention of RSV infection in children:</strong></p>
<ul>
<li><strong>Respiratory Syncytial Virus (RSV)</strong> can cause serious lower respiratory tract infections in infants and children. The FDA has approved <strong>Nirsevimab</strong>, a novel drug, to prevent RSV infection. Nirsevimab is primarily used to treat <strong>neonates</strong> and <strong>infants </strong>born during an RSV outbreak (between June and October) and can extend to children too.</li>
</ul>
<p><strong>Mechanism of Action: </strong></p>
<ul>
<li>Nirsevimab is a <strong>monoclonal antibody</strong> that <strong>blocks viral entry</strong> into the host cell.</li>
</ul>
<p><strong>Dosage and Administration: </strong></p>
<ul>
<li>Nirsevimab is administered as an <strong>intramuscular injection</strong>.</li>
</ul>
<p>For <strong>neonates and infants</strong></p>
<ul>
<li><strong>50 mg</strong> if body weight <strong>&lt; 5 kg</strong></li>
<li><strong>100 mg</strong> if body weight <strong>&ge; 5 kg</strong></li>
</ul>
<p>For vulnerable <strong>children</strong> up to 24 months of age</p>
<ul>
<li><strong>100 mg</strong> injections given <strong>twice </strong></li>
</ul>
<p><strong>Precautions </strong></p>
<ul>
<li>Hypersensitivity reaction</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 17</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>What is the theme of World TB Day 2024? (National Health Programms, Communicable Diseases, Community Health Nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Yes! We can end TB!</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>It&rsquo;s time to end TB</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Invest to End TB. Save Lives</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The clock is ticking</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The theme of world TB day 2024 is <strong>'Yes! We can end TB!</strong></p>
<p><strong>World Tuberculosis Day</strong> is observed on <strong>24<sup>th</sup> March</strong> of every year.</p>
<p>The themes of the other world TB days are:</p>
<ul>
<li>The theme of 2024 is, 'Yes! We can end TB!' previously in the year 2023 the theme was same as that of 2024.</li>
<li>2022: Invest to End TB. Save Lives</li>
<li>2021: The clock is ticking</li>
<li>2020: It's time to end TB</li>
<li>2019: It's time for action</li>
<li>2018: Wanted: Leaders for a TB-free world</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 18</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>The MOHFW has announced a mission to eliminate sickle cell disease by ___________. (National Health Programs, Non-communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>2030</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>2040</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>2047</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>2050</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Mission- Eliminate sickle cell disease 2047 </strong></p>
<ul>
<li>The MOHFW has announced a mission to <strong>eliminate</strong> sickle cell disease (SCD) by <strong>2047 </strong>with a goal to ensure <strong>universal screening</strong> of <strong>7 crore people</strong> between 0-40 years in affected tribal areas.</li>
<li>The <strong>Standard Treatment Workflow for Sickle Cell Disease</strong> has been prepared by ICMR to achieve this goal. According to this, the following groups will be screened to detect SCD:
<ul>
<li>Antenatal mothers or pre-pregnancy planning</li>
<li>Newborn</li>
<li>Population screening/patient of any age</li>
</ul>
</li>
<li><strong>Prophylaxis</strong> plans include penicillin, immunizations, folic acid supplementation, and vaccinations against pneumococcal infection, meningococcal infection, H-influenza, typhoid, influenza, and COVID-19.</li>
<li>The guidelines provide <strong>specific dosing</strong> instructions for <strong>hydroxyurea</strong>.
<ul>
<li>Infants and children - 10-15 mg/kg/day</li>
<li>Adolescents - 15 mg/kg/day</li>
<li>CBC monitoring every 1-3 months</li>
</ul>
</li>
<li>The only <strong>curative therapy</strong> is <strong>stem cell transplantation</strong> and is reserved only for those patients who do not respond to other treatment options.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 19</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Open vial policy is not applicable to which of the following vaccines? (Immunization and vaccines, Introduction to epidemiology, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hepatitis B</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>BCG</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pentavalent vaccine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rota viral vaccine in New container</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Open vial policy is not applicable for BCG and measles vaccines.</p>
<p><strong>It is applicable for: </strong></p>
<ul>
<li>DPT</li>
<li>TT</li>
<li>Hepatitis B vaccine</li>
<li>OPV</li>
<li>Pentavalent vaccine</li>
<li>Rotavirus vaccine (new version with the VVM on the side)</li>
</ul>
<p><strong>Open Vial Policy</strong></p>
<ul>
<li>Open vial policy allows for reuse of partially used <strong>multidose vials</strong> of applicable vaccines under the Universal Immunization Programme in subsequent sessions up to <strong>4 weeks&rsquo;</strong> subject to certain conditions and thereby reducing vaccine wastage.</li>
<li>It is applicable only for <strong>DPT, TT, hepatitis B vaccine, OPV, liquid pentavalent vaccine, rotavirus vaccine (new version with the VVM on the side),</strong> and <strong>JE vaccines (inactivated).</strong> It is not applicable <strong>to BCG and measles vaccines</strong>.</li>
<li>Vaccine vials opened in session-site can be used in more than one session up to four weeks if <strong>expiry date has not passed</strong>, <strong>if storage and transport was appropriate, no contamination has occurred in vial septum, asepsis in withdrawing was practiced and if vaccine vial monitor has not reached discard point</strong>.</li>
<li>Open vials should <strong>not</strong> be submerged in water. All open vials should have a record of <strong>date and time of opening</strong>. At the end of a session, all vaccines should be returned to the cold chain point and segregated as re-usable and non-reusable. All open vials of BCG, measles must be destroyed after 48 hours or before next session, whichever is earlier.</li>
<li>In case of any <strong>adverse events following immunization</strong>, all open vials should not be discarded until investigation is complete. All vials must be transported in zipper bags in the vaccine carrier and recorded in stock register. Ice packs used should be well sealed.</li>
</ul>
<p><strong>Updated Rotavac with open vial policy </strong></p>
<ul>
<li>MOHFW has updated VVM guidelines on the <strong>oral Rotavac</strong> vaccine to change the <strong>location of the Vaccine Vial Monitor</strong>, which was initially on the cap of the vial, <strong>to the label</strong> of the vaccine vial.</li>
<li>The <strong>open multi-dose policy</strong> is applicable <strong>only </strong>to this <strong>new presentation</strong> of the vaccine. Implementation of the Open Vial Policy allows the reuse of partially used multi-dose vials of applicable vaccines under the universal immunization policy to prevent wastage of medication.</li>
<li>The vaccine schedule will remain the same, that is a <strong>3-dose schedule</strong> at 6 weeks, 10 weeks, and 14 weeks. It is to be stored at -<strong>50&deg;C to -25&deg;C</strong> till district stores and then at <strong>2&deg;C to 8&deg;C</strong> at the <strong>sub-district</strong></li>
</ul>
<p><strong><img title="image007.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/23c329b9-c821-4fe7-810e-524b00620844.jpg" alt="" width="381" height="250" /></strong></p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 20</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which strain of the Ebola virus has the highest case fatality rate? (Zoonotic diseases, Communicable diseases and National Health Programs, Community health nursing)</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Zaire strain</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Sudan strain</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Reston strain</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Ta&iuml; Forest strain</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The <strong>Zaire strain</strong> has a <strong>case fatality rate of 90%.</strong></li>
<li>There are <strong>five identified Ebola virus strains</strong>, four of which are known to cause disease in humans:
<ul>
<li><strong>Ebola virus</strong> (Zaire ebolavirus)</li>
<li><strong>Sudan virus</strong> (Sudan ebolavirus)</li>
<li><strong>Ta&iuml; Forest virus</strong> (Ta&iuml; Forest ebolavirus)</li>
<li><strong>Bundibugyo virus</strong> (Bundibugyo ebolavirus).</li>
</ul>
</li>
<li>The fifth, Reston virus (Reston ebolavirus), has caused disease in nonhuman primates, but not in humans.</li>
<li>The Bundibugyo ebolavirus, Zaire ebolavirus, and Sudan ebolavirus have been associated with large outbreaks in Africa. The strain that caused the 2014-2016 West African outbreak belongs to the Zaire ebolavirus species.</li>
<li>On 14th October 2020, the U.S. Food and Drug Administration (FDA) approved Inmazeb (Atoltivimab, Maftivimab, and Odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.</li>
</ul>
</body>
</html></li></ul></div></div>
        <div class="credits">
            <p class="rainbow-text">Credit: Code Written by BHASKAR</p>
        </div>
        </body></html>